The following academic unit formed the submission to UoA 8:
- School of Chemistry
- A Faculty reorganisation in summer 2017 saw Chemistry become part of the new School of Natural and Environmental Sciences
Within the School there were four research groups submitted to UoA 8:
- Bio-Medicinal Chemistry
- Catalysis and Synthesis
- Chemical Nanoscience
- Spectroscopy and Structural Chemistry
The research in Chemistry has now changed to three research areas.
Key strengths lie in the areas of:
- fundamental aspects of the chemistry/medicine interface and the development of drugs
- new electronic materials
- environmental sustainability
- understanding the properties of molecular-based materials
The following case studies demonstrate the impact of our research:
Development of the first-in-class poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor Rucaparib (AG014699, PF-01367338)Development of the first-in-class poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor Rucaparib (AG014699, PF-01367338)
The case study relates to the landmark discovery and clinical development of Rucaparib, an agent that enhances the activity of DNA-damaging cancer therapies. Annually, >12 million people worldwide are diagnosed with cancer, whilst about eight million persons die from the disease.
A collaboration was established in 1990 between the School of Chemistry and Newcastle Medical School (and later with pharmaceutical industry partners) that led to the discovery of potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP-1). This enzyme enables cancer cells to survive drug treatments or radiotherapy. Based on a concept and design of Professors Bernard Golding and Roger Griffin, a series of benzimidazole carboxamides was synthesised in the School of Chemistry, which led to a potent and selective PARP-1 inhibitor (PF-01367338, Rucaparib).
Find out more:
- Professor Bernard T Golding
- Professor Roger J Griffin
The provision of novel compounds for the pharmaceutical industry via the Newcastle University based company NewChemThe provision of novel compounds for the pharmaceutical industry via the Newcastle University based company NewChem
Based on his innovative research in organic synthesis and medicinal chemistry at Newcastle University, Professor Bernard Golding has created an SME, NewChem, which provides a bespoke synthetic and analytical service to the pharmaceutical industry. NewChem research has played a major role in providing its partner Shire Pharmaceuticals with potential new drugs for treating a range of therapeutic indications, eg thrombotic cardiovascular disorders, dementias and ADHD.
During its 10-year lifetime, the company has provided > 100 FTE of employment for chemists housed in Newcastle University's School of Chemistry. NewChem provides income and support to the University both through its usage of space and facilities, but also through the training of postgraduate and undergraduate students.
Find out more:
Development and exploitation of UK synchrotron facilities for crystal structure determination in chemistry and materials science: impact on other inteDevelopment and exploitation of UK synchrotron facilities for crystal structure determination in chemistry and materials science: impact on other inte
A 1990s Newcastle-led research project to construct the world’s first ever dedicated single-crystal diffraction synchrotron beamline for chemistry and materials science at Daresbury Laboratory SRS, led to an innovative and productive international facility that was widely used in academic and commercial research at that site. It has served as the model for the development of more recent facilities in the UK (Diamond Light Source) and elsewhere.
Results from SRS and the newer facilities have been critically important for the advancement of the chemical and pharmaceutical industries, and the original Newcastle research has also trained scientists now employed in industry and public service internationally.
Find out more:
Find out about all our REF 2014 results.